Table 3 Risk factors affecting PFS in MM patients
From: Prognostic marker CD27 and its micro-environmental in multiple myeloma
Risk factor | Univariate analysis HR 95%CI P value | Multivariate analysis HR 95%CI P value |
|---|---|---|
ISS stage III | 1.957 1.094–3.500 0.024 | 0.873 0.387–1.971 0.744 |
Cr ≥ 115 μmol/L | 1.031 0.589–1.805 0.915 | |
CD27 + T ≥ 20% | 4.147 2.015–8.535 0.000 | 3.759 1.730–8.168 0.001 |
BMPC ≥ 31.49% | 1.807 1.054–3.099 0.032 | 1.143 0.630–2.075 0.659 |
Ca ≥ 2.75mmlo/L | 0.891 0.459–1.729 0.733 | |
HB < 100 g/L | 0.726 0.420–1.254 0.251 | |
LDH > 246U/L | 0.712 0.420–1.209 0.209 | |
ALB < 35 g/L | 1.402 0.818–2.402 0.219 | |
Age ≥ 65 | 1.940 1.128–3.338 0.017 | 2.068 1.068–4.003 0.031 |
β2-MG ≥ 3.5 μmol/L | 2.556 1.431–4.565 0.002 | 1.433 0.689–2.981 0.336 |
Therapeutic schemes | 0.662 0.388–1.130 0.131 |